Navigation Links
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
Date:6/8/2009

-Hodgkin's lymphoma (63% ORR), Hodgkin's disease (53% ORR), follicular lymphoma (50% ORR), mantle cell lymphoma (32% ORR), DLBCL (30% ORR) and small lymphocytic lymphoma (18% ORR)(1).

Patients received everolimus 10 mg daily and were evaluated monthly. Dose reductions to 5 mg daily and 5 mg every other day were permitted. Response was assessed after two cycles of treatment and periodically thereafter. Patients received a median of three cycles(1). Overall, everolimus was well tolerated. The most commonly reported adverse events (grade 3 or 4; >10% patients) in this heavily pretreated population included anemia, neutropenia and thrombocytopenia(1).

About non-Hodgkin's lymphoma and Hodgkin's disease

Non-Hodgkin's lymphoma and Hodgkin's disease manifest in the cells of the lymphatic system, which is composed of lymphoid tissue, lymph vessels and lymph fluid that help the body filter out bacteria and fight disease. Since lymphatic tissue is located throughout the body, NHL and Hodgkin's disease can start almost anywhere(2,7,8). The most recent data indicate that more than 300,000 new cases of NHL develop around the world each year(9).

About Afinitor

Afinitor has been approved by the US Food and Drug Administration (FDA) as the first oral, daily therapy (5 mg and 10 mg tablets) to treat advanced kidney cancer after failure of treatment with sunitinib or sorafenib. Recently, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion supporting EU approval of Afinitor to treat patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

In cancer cells, Afinitor continuously targets mTOR, a protein that acts as a central regulator of tumor cell division, blood vessel growth and cell metabolism. Novartis has also filed regulatory su
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... second quarter ending June 30, 2015. ... We are excited to be near the completion of ... with topline results expected in the fourth quarter," stated ... Inc. "Translarna is now commercially available in 12 countries ...
(Date:7/30/2015)... 30, 2015 Eisai Inc. announced today that ... United States , European Union and ... respectively) for eribulin, for the treatment of patients with ... chemotherapy for advanced or metastatic disease. ... pivotal global Phase 3 clinical trial (Study 309), which ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... Oct. 7 /PRNewswire-Asia/ -- ... ... var ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... Oct. 7 Marine biotechnology specialist Azantis, Inc ... to its clients, in an effort to provide continued ... an agreement with SafetyCall International , Azantis has ... and Post-Market Surveillance services. SafetyCall medical ...
Cached Medicine Technology:Professor Steven V. Ley Speaks at WuXi PharmaTech 2Professor Steven V. Ley Speaks at WuXi PharmaTech 3Professor Steven V. Ley Speaks at WuXi PharmaTech 4Professor Steven V. Ley Speaks at WuXi PharmaTech 5Professor Steven V. Ley Speaks at WuXi PharmaTech 6Professor Steven V. Ley Speaks at WuXi PharmaTech 7Azantis Announces New Consumer Safety Program 2
(Date:8/1/2015)... ... , ... On Tuesday, July 28th, Symantec released a security industry whitepaper ... the attack on Anthem Inc. which resulted in one of the largest data breaches ... spear phishing campaigns. , For Joe Caruso, founder and CEO/CTO of ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, the STASH ... STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured ... tried-and-true products that have stood the test of time. These include lighting products, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a ... going on in Chicago at Grant Park. The festival will end on Sunday, ... America to Chicago for the annual Lollapalooza. This unique and unbelievably popular festival ...
(Date:7/31/2015)... ... ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest applicator for ... applicator in the United States as an upgrade to the CoolSmooth applicator cleared by ... required a 2 hour treatment time. The new CoolSmooth Pro reduces the treatment ...
(Date:7/31/2015)... ... , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam Prep ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust selection ... exam easy and painless. MDLinx offers thousands of board-exam style questions and exam-specific ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... , , , MINNEAPOLIS, ... and marketer of state-of-the-art cardiac surgery products and services, today reported financial ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ) , , Second ... or 17.0% higher than the second quarter of 2008. Revenue from ...
... CRANBURY, N.J., Aug. 3 Innophos Holdings, Inc. (Nasdaq: ... financial results for the second quarter 2009. , , ... Net sales for the second quarter 2009 were $166.8 million, ... the same period in 2008. Selling price increases had a positive effect ...
... , , SAN DIEGO, Aug. ... financial results for the second quarter ended June 30, 2009. , ... in the second quarter of 2009 of $38.0 million, or $0.48 per share, ... of 2008 of $65.8 million, or $0.89 per share, and a net loss ...
... , , BIRMINGHAM, Ala., Aug. 3 ... reports Operating Income of $50.4 million, or $1.52 per diluted share for ... million, or $1.62 per diluted share. For the six months ended June ... and Net Income was $82.2 million, or $2.46 per diluted share. , ...
... NEW YORK, Aug. 3 The uninsured issue has become a ... are currently without health insurance, a number that is continuing to ... large hospitals and clinics for sick visits and emergencies -- as ... patients arrive at hospitals and clinics, by State law, the facility ...
... a good time with friends, researchers say, , MONDAY, Aug. ... why one in 10 high school seniors have tried opioid ... reasons included relaxation, feeling good or getting high, experimentation and ... hydrocodone, oxycodone, hydromorphone, meperidine, morphine and codeine without a prescription, ...
Cached Medicine News:Health News:ATS Medical Announces Second Quarter 2009 Results 2Health News:ATS Medical Announces Second Quarter 2009 Results 3Health News:ATS Medical Announces Second Quarter 2009 Results 4Health News:ATS Medical Announces Second Quarter 2009 Results 5Health News:ATS Medical Announces Second Quarter 2009 Results 6Health News:ATS Medical Announces Second Quarter 2009 Results 7Health News:ATS Medical Announces Second Quarter 2009 Results 8Health News:ATS Medical Announces Second Quarter 2009 Results 9Health News:ATS Medical Announces Second Quarter 2009 Results 10Health News:ATS Medical Announces Second Quarter 2009 Results 11Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 2Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 3Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 4Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 5Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 6Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 7Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 8Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 9Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 10Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 11Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 12Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 13Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 14Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 15Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 2Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 3Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 4Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 5Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 6Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 7Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 8Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 9Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 10Health News:ProAssurance Reports Second Quarter 2009 Results 2Health News:ProAssurance Reports Second Quarter 2009 Results 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: